Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics
AbstractThousands of samples for pharmacogenetic tests have been analysed in our laboratory since its establishment. In this article we describe some of the most interesting cases of CYP poor metabolisers associated with adverse reactions to psychotropic drugs. Prevention of disease/illness, including Adverse Drug Reaction (ADR), is an aim of modern medicine. Scientific data supports the fact that evaluation of drug toxicology includes several factors, one of which is genetic variations in pharmacodynamics and pharmacokinetics of drug pathways. These variations are only a part of toxicity evaluation, however, even if it would help to prevent only a small percentage of patients from suffering adverse drug reactions, especially life threatening ADRs, pharmacogenetic testing should play a significant role in any modern psychopharmacologic practice. Medical practitioners should also consider the use of other medications or alternative dosing strategies for drugs in patients identified as altered metabolisers. This will promise not only better and safer treatments for patients, but also potentially lowering overall healthcare costs.
- Supplementary File 1:
PDF-Document (PDF, 182 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Piatkov, I.; Jones, T.; McLean, M. Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics. J. Pers. Med. 2012, 2, 149-157.
Piatkov I, Jones T, McLean M. Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics. Journal of Personalized Medicine. 2012; 2(4):149-157.Chicago/Turabian Style
Piatkov, Irina; Jones, Trudi; McLean, Mark. 2012. "Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics." J. Pers. Med. 2, no. 4: 149-157.